AbCellera Biologics Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-55.4M | $-43.2M | $-57.1M | $-34.7M | $-45.6M | $-51.1M | $-36.9M | $-40.6M |
| Depreciation & Amortization | $7.0M | $6.8M | $5.2M | $5.5M | $5.3M | $36.9M | $36.5M | $4.8M |
| Depreciation | $6.1M | $5.9M | $4.3M | $4.6M | $4.4M | $3.8M | $3.4M | $3.2M |
| Amortization | — | $920.0K | — | — | $922.0K | — | — | $1.7M |
| Stock-Based Compensation | — | $12.0M | — | — | $14.8M | — | — | $17.4M |
| Net Cash from Operating Activities | $25.9M | $-33.5M | $-52.6M | $-32.4M | $-11.6M | $-28.9M | $-30.0M | $-41.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.1M | $3.8M | $8.9M | $13.4M | $10.6M | $18.5M | $20.1M | $24.1M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $-25.1M | — | — | $7.9M | — | — | $29.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $7.2M | — | — | $6.0M | — | — | $2.8M |
| Net Change in Cash | — | $-51.5M | — | — | $2.9M | — | — | $-9.7M |
| Free Cash Flow | $23.8M | $-37.4M | $-61.5M | $-45.8M | $-22.2M | $-47.4M | $-50.1M | $-65.8M |